As an independent strategy advisor with deep experience across global pharma, CDMO partnering, and go-to-market planning, I work closely with companies looking to: Assess competitive positioning in peptide APIs and intermediates Navigate the patent cliff with a region-specific GTM strategy Identify potential partners, licensing pathways, and supply-side opportunities If youre planning your next move in the GLP-1 space, lets talk
Andrew Huberman Peptides: How a Regular Patient Would Get Access At a glance Andrew Huberman has discussed BPC-157, TB-500, Sermorelin, and GHK-Cu on the Huberman Lab podcast The FDA banned bulk compounding of several peptides in late 2023 under its Category 2 list BPC-157 and TB-500 are not FDA-approved drugs and carry limited human trial data Sermorelin and CJC-1295/Ipamorelin remain available through 503A/503B compounding pharmacies Insurance almost never covers compounded peptide prescriptions A prescriber visit, baseline labs, and follow-up monitoring are standard requirements Telemedicine peptide clinics have expanded access but vary widely in clinical rigor The Endocrine Society has not endorsed peptide secretagogues for anti-aging use What Peptides Has Andrew Huberman Discussed
The better practical choice is healthy skin in an allowed area that you can use correctly
Ozempic and Mounjaro can be used alone or together with other diabetes medications
Quick absorption helps with energy boosts
You May Also Like Frequently Asked Questions Can I take a GLP-1 nutrition support shake without GLP-1 medication
